SOLICITATION NOTICE
65 -- Reagents
- Notice Date
- 1/7/2016
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services - Philadelphia, 200 Chestnut Street, Room 900, Philadelphia, Pennsylvania, 19106, United States
- ZIP Code
- 19106
- Solicitation Number
- FDA-1159340
- Archive Date
- 2/5/2016
- Point of Contact
- Janice Heard, Phone: 215-717-3093
- E-Mail Address
-
janice.heard@fda.hhs.gov
(janice.heard@fda.hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- Notice of Intent to Award a Sole Source Contract - FDA1159340 Description(s): Establishment of a 3-year IDIQ contract for the purchase of sequencing reagents for the MiSeq® and NextSeq® Instruments manufactured by Illumina. The U.S. Food and Drug Administration intends to make a sole source award to Illumina, Inc. for sequencing reagents for the MiSeq® and NextSeq® Instrument. The reagents, specifically produced by the manufacturer (Illumina), are required to perform sequencing with the MiSeq® and NextSeq® Instruments. MiSeq kits use an all-inclusive reagent cartridge system that is specifically designed to deliver the reagents necessary for cluster generation, sequencing, and paired-end chemistry.The MiSeq system uses a flow cell that is specifically designed for the instruments. This procurement will be for the following reagents: Part# Description MS-102-3003 - MiSeq Reagent Kit V3 (600 cycle) FC-131-1096 - Nextera® XT DNA Sample Preparation Kit (96 Samples) FC-131-2001 - Nextera® XT Index Kit V2 Set A (96 Indices, 384 Samples) FC-131-2002 - Nextera® XT Index Kit v2 Set B (96 Indices, 384 Samples) FC-131-2003 - Nextera® XT Index Kit V2 Set C (96 Indices, 384 Samples) FC-131-2004 - Nextera® XT Index Kit V2 Set D (96 Indices, 384 Samples) FC-110-3002 - NextSeq TM PhiX Control Kit V3 The period of performance will be for a total of 36 months and an IDIQ type of contract (allowing for firm-fixed priced delivery orders) is anticipated. The NAICS Code for this action is 541711 - Research and Development in Biotechnology. This procurement is made under the authority of 10 USC 2304(c) (1) and pursuant to FAR 6 - only one responsible source. This is a notice of intent to issue this solicitation on a sole source basis to Illumina. This notice of intent is not a solicitation for competitive proposals. Any other firm desiring consideration must fully identify their interest and capability to provide these items by submitting a capability statement to Janice Heard at janice.heard@fda.hhs.gov no later than January 21, 2016. A determination by the Government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. The projected award date is May 2, 2016. Period of performance: Base Year: May 2, 2016 thru May, 01, 2017; Option Year One: May 2, 2017 thru May 1, 2018, if exercised; Option Year Two: May 2, 2018 thru May 1, 2019, if exercised; Primary Point of Contact: Janice Heard Contract Specialist Janice.Heard@fda.hhs.gov Phone: 215-717-3093 Contracting Office Address: 200 Chestnut Street, Rm 900 U.S. Customhouse Philadelphia, PA 19106
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/2e05ad697266ce2a51a8de8f86cabee7)
- Place of Performance
- Address: Food & Drug Administration, 8401 Muirkirk Road, Laurel, Maryland, 20708, United States
- Zip Code: 20708
- Zip Code: 20708
- Record
- SN03985984-W 20160109/160107235008-2e05ad697266ce2a51a8de8f86cabee7 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |